Aethlon Medical, Inc. (AEMD)
| Market Cap | 3.30M -40.1% |
| Revenue (ttm) | n/a |
| Net Income | -11.52M |
| EPS | -28.51 |
| Shares Out | 1.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,303 |
| Open | 2.140 |
| Previous Close | 2.140 |
| Day's Range | 2.100 - 2.195 |
| 52-Week Range | 1.360 - 34.048 |
| Beta | 1.50 |
| Analysts | Hold |
| Price Target | 15.00 (+614.29%) |
| Earnings Date | Jun 25, 2026 |
About AEMD
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices to treat cancer and viral infections in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for AEMD stock is "Hold" and the 12-month stock price target is $15.0.
News
Aethlon Medical Transcript: Emerging Growth Conference 91
An Australian oncology trial is advancing to its final cohort after positive safety review, focusing on optimizing Hemopurifier treatments for patients unresponsive to leading immunotherapies. Data on immune and exosome changes are expected this quarter.
Advancements in Novel Immunotherapeutics in The Oncology Battle
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immun...
Aethlon Medical advances to final cohort in AEMD-2022-06 trial
Aethlon Medical (AEMD) announced that the independent Data Safety Monitoring Board overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort par...
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device fo...
Aethlon Medical Transcript: Life Sciences Virtual Investor Forum
Hemopurifier, a unique device targeting cancer-related EVs, is progressing through a safety trial in Australia with positive early data and a strong cash position. Key milestones include advancing to an efficacy trial and seeking strategic partnerships for broader development.
Aethlon Medical to evaluate range of strategic opportunities
Aethlon Medical (AEMD) announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group to act as the company’s exclusive financial advisor in connection with this…
Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threa...
Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC...
Aethlon Medical Transcript: Emerging Growth Virtual Conference
Hemopurifier clinical trials are advancing in Australia, focusing on solid tumor patients unresponsive to immunotherapy. Operational improvements and new patient recruitment strategies have accelerated progress, with key safety and efficacy data expected in the coming months.
Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SAN DIEGO, Feb. 23, 2026 /...
Aethlon Medical Earnings Call Transcript: Q3 2026
Australian oncology trial for Hemopurifier advanced with strong patient recruitment and cost controls. Operating expenses fell 27% year-over-year for the nine-month period, and compatibility work with the SLAMB system could broaden future clinical use.
Aethlon Medical reports Q3 EPS ($2.45) vs. ($10.05) last year
As of December 31, 2025, Aethlon had a cash balance of approximately $7M. “We remain committed to advancing our clinical programs and research initiatives with operational discipline,” said James Frak...
Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (th...
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
SAN DIEGO, Feb. 4, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, tod...
Aethlon Medical files to sell 2.03M shares of common stock for holders
16:17 EST Aethlon Medical (AEMD) files to sell 2.03M shares of common stock for holders
Aethlon Medical files to sell $15M of common stock
15:09 EST Aethlon Medical (AEMD) files to sell $15M of common stock
Aethlon Medical announces $3.3M private placement
Aethlon Medical (AEMD) announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 595,897 shares of common stock, together with warrants to pur...
Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
SAN DIEGO , Dec. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threat...
Aethlon Medical’s Hemopurifier shows potential efficacy in long COVID
Aethlon Medical (AEMD) announced the 20 November 2025 publication of a pre-clinical study in the pre-print online archive bioRxiv, simultaneously been submitted for consideration to a peer-reviewed jo...
Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs
Results Support the Further Investigation of the Hemopurifier in Long COVID SAN DIEGO , Dec. 2, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on deve...
Aethlon Medical Earnings Call Transcript: Q2 2026
Q2 2026 saw a 48% reduction in operating expenses and progress in the Australian oncology trial, with cohort one showing positive safety data and cohort two recruitment underway. Focus remains on oncology and Long COVID, with ongoing efforts to optimize spending and accelerate trial enrollment.
Aethlon Medical reports Q2 EPS ($3.74) vs. ($16.11) last year
As of September 30, 2025, Aethlon had a cash balance of approximately $5.8M. “We remain focused on executing our clinical and research strategy while maintaining operational discipline,” said James Fr...
Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
Clinical and research progress continues alongside substantial cost reductions. Conference Call Today at 4:30 p.m.
Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to...
Aethlon Medical trading halted, news pending
19:50 EDT Aethlon Medical (AEMD) trading halted, news pending